Related Experiment Video
Updated: Jun 13, 2026

Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens
Published on: May 23, 2014
Progestogens reduce thromboxane production by cultured human endothelial cells
P J Oviedo1, A Sobrino, S Novella
1Research Foundation, Hospital Clínico Universitario, University of Valencia, Valencia, Spain.
Progesterone and medroxyprogesterone acetate reduce thromboxane A2 release from endothelial cells. These progestogens also increase prostacyclin synthase, mediated by progesterone receptors.
Area of Science:
- Endocrinology
- Vascular Biology
- Reproductive Medicine
Background:
- Progestogens' roles in endothelial physiology are understudied.
- Prostanoids, like thromboxane A2 (vasoconstrictor) and prostacyclin (vasodilator), significantly impact vascular function.
- Understanding progestogen effects on these pathways is crucial for cardiovascular health.
Purpose of the Study:
- To investigate the impact of progesterone and medroxyprogesterone acetate on thromboxane A2 production in human umbilical vein endothelial cells (HUVEC).
- To explore the involvement of progesterone receptors and key enzymes in regulating thromboxane A2 and prostacyclin synthesis.
- To elucidate the mechanisms underlying progestogen-mediated vascular effects.
Main Methods:
- HUVEC were treated with varying concentrations of progesterone or medroxyprogesterone acetate.
- Thromboxane A2 levels were quantified using enzyme immunoassay.
- Gene and protein expression of prostacyclin synthase and thromboxane synthase were analyzed via qPCR and Western blot, respectively.
- The role of progesterone receptors was assessed using a specific antagonist (RU486).
Main Results:
- Both progesterone and medroxyprogesterone acetate significantly reduced thromboxane A2 release after 24 hours.
- Progestogen exposure led to increased gene and protein expression of prostacyclin synthase.
- Thromboxane synthase expression remained unchanged.
- The observed effects were dependent on progesterone receptor activation, as demonstrated by the antagonist RU486.
- Cyclo-oxygenase-1 inhibition further reduced thromboxane release.
Conclusions:
- Progesterone and medroxyprogesterone acetate decrease thromboxane release from HUVEC in a progesterone receptor-dependent manner.
- These progestogens enhance prostacyclin synthase expression at both gene and protein levels.
- The findings highlight a novel mechanism by which progestogens may influence vascular tone and endothelial function.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
